Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 665

1.

Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe.

Massy ZA, Caskey FJ, Finne P, Harambat J, Jager KJ, Nagler E, Stengel B, Sever MS, Vanholder R, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Soler MJ, Rychlík I, Spasovski G, Stevens K, Wanner C, Zoccali C.

Nephrol Dial Transplant. 2019 Jun 14. pii: gfz089. doi: 10.1093/ndt/gfz089. [Epub ahead of print]

PMID:
31197325
2.

Why systematic literature reviews in fabry disease should include all published evidence.

Elliott PM, Germain DP, Hilz MJ, Spada M, Wanner C, Falissard B.

Eur J Med Genet. 2019 Jun 10:103702. doi: 10.1016/j.ejmg.2019.103702. [Epub ahead of print] Review.

PMID:
31195166
3.

Mendelian Randomization analysis reveals a causal influence of circulating sclerostin levels on bone mineral density and fractures.

Zheng J, Maerz W, Gergei I, Kleber M, Drechsler C, Wanner C, Brandenburg V, Reppe S, Gautvik KM, Medina-Gomez C, Shevroja E, Gilly A, Park YC, Dedoussis G, Zeggini E, Lorentzon M, Henning P, Lerner UH, Nilsson K, Movérare-Skrtic S, Baird D, Elsworth B, Falk L, Groom A, Capellini TD, Grundberg E, Nethander M, Ohlsson C, Smith GD, Tobias JH.

J Bone Miner Res. 2019 Jun 6. doi: 10.1002/jbmr.3803. [Epub ahead of print]

PMID:
31170332
4.

Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.

Butler J, Zannad F, Fitchett D, Zinman B, Koitka-Weber A, von Eynatten M, Zwiener I, George J, Brueckmann M, Cheung AK, Wanner C.

Circ Heart Fail. 2019 Jun;12(6):e005875. doi: 10.1161/CIRCHEARTFAILURE.118.005875. Epub 2019 Jun 5.

PMID:
31163986
5.

[Diabetic Kidney Disease - How to Protect the Kidney?]

Brenner S, Wanner C.

Dtsch Med Wochenschr. 2019 Jun;144(11):710-714. doi: 10.1055/a-0662-1919. Epub 2019 Jun 4. German.

PMID:
31163466
6.

Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.

Mayer GJ, Wanner C, Weir MR, Inzucchi SE, Koitka-Weber A, Hantel S, von Eynatten M, Zinman B, Cherney DZI.

Kidney Int. 2019 Mar 21. pii: S0085-2538(19)30317-5. doi: 10.1016/j.kint.2019.02.033. [Epub ahead of print]

PMID:
31142441
7.

CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle.

Schernthaner G, Wanner C, Jurišić-Eržen D, Guja C, Gumprecht J, Jarek-Martynowa IR, Karasik A, Lalić N, Mankovsky BN, Prázný M, Tankova T, Tsur A, Wascher TC, Wittmann I.

Diabetes Res Clin Pract. 2019 May 20;153:30-40. doi: 10.1016/j.diabres.2019.05.013. [Epub ahead of print]

PMID:
31121272
8.

Mild cognitive impairment and kidney disease: clinical aspects.

Viggiano D, Wagner CA, Blankestijn PJ, Bruchfeld A, Fliser D, Fouque D, Frische S, Gesualdo L, Gutiérrez E, Goumenos D, Hoorn EJ, Eckardt KU, Knauß S, König M, Malyszko J, Massy Z, Nitsch D, Pesce F, Rychlík I, Soler MJ, Spasovski G, Stevens KI, Trepiccione F, Wanner C, Wiecek A, Zoccali C, Unwin R, Capasso G.

Nephrol Dial Transplant. 2019 Apr 9. pii: gfz051. doi: 10.1093/ndt/gfz051. [Epub ahead of print] No abstract available.

PMID:
31071220
9.

Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

House AA, Wanner C, Sarnak MJ, Piña IL, McIntyre CW, Komenda P, Kasiske BL, Deswal A, deFilippi CR, Cleland JGF, Anker SD, Herzog CA, Cheung M, Wheeler DC, Winkelmayer WC, McCullough PA; Conference Participants.

Kidney Int. 2019 Jun;95(6):1304-1317. doi: 10.1016/j.kint.2019.02.022. Epub 2019 Apr 30.

PMID:
31053387
10.

Erratum to Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials

Zoccali C, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Ketteler M, Massy Z, Rychlık I, Soler MJ, Stevens K, Spasovski G, Wanner C.

Nephrol Dial Transplant. 2019 Apr 12. pii: gfz070. doi: 10.1093/ndt/gfz070. [Epub ahead of print] No abstract available.

PMID:
30977814
11.

Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes.

Verma S, Wanner C, Zwiener I, Ofstad AP, George JT, Fitchett D, Zinman B; EMPA-REG OUTCOME Investigators.

J Am Coll Cardiol. 2019 Jun 4;73(21):2780-2782. doi: 10.1016/j.jacc.2019.03.002. Epub 2019 Mar 15. No abstract available.

PMID:
30885684
12.

Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.

Savarese G, Sattar N, Januzzi J, Verma S, Lund LH, Fitchett D, Zeller C, George JT, Brueckmann M, Ofstad AP, Inzucchi SE, Wanner C, Zinman B, Butler J.

Circulation. 2019 Mar 12;139(11):1458-1460. doi: 10.1161/CIRCULATIONAHA.118.038339. No abstract available.

PMID:
30855996
13.

Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials.

Zoccali C, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Ketteler M, Massy Z, Rychlık I, Soler MJ, Stevens K, Spasovski G, Wanner C.

Nephrol Dial Transplant. 2019 Feb 27. pii: gfz023. doi: 10.1093/ndt/gfz023. [Epub ahead of print]

PMID:
30815678
14.

Dyshidrosis is associated with reduced amplitudes in electrically evoked pain-related potentials in women with Fabry disease.

Siedler G, Káhn AK, Weidemann F, Wanner C, Sommer C, Üçeyler N.

Clin Neurophysiol. 2019 Apr;130(4):528-536. doi: 10.1016/j.clinph.2019.01.008. Epub 2019 Feb 4.

PMID:
30785009
15.

Left Ventricular Structure in Patients With Mild-to-Moderate CKD-a Magnetic Resonance Imaging Study.

Schneider MP, Scheppach JB, Raff U, Toncar S, Ritter C, Klink T, Störk S, Wanner C, Schlieper G, Saritas T, Reinartz SD, Floege J, Friedrich N, Janka R, Uder M, Schmieder RE, Eckardt KU.

Kidney Int Rep. 2018 Oct 11;4(2):267-274. doi: 10.1016/j.ekir.2018.10.004. eCollection 2019 Feb.

16.

The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts.

Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, Kantola I, Linhart A, Mignani R, Namdar M, Nowak A, Oliveira JP, Pieroni M, Viana-Baptista M, Wanner C, Spada M.

Mol Genet Metab Rep. 2019 Feb 6;19:100454. doi: 10.1016/j.ymgmr.2019.100454. eCollection 2019 Jun. Review.

17.

Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline.

Januzzi J, Ferreira JP, Böhm M, Kaul S, Wanner C, Brueckmann M, Petrie MC, Ofstad AP, Zeller C, George J, Fitchett D, Zannad F.

Eur J Heart Fail. 2019 Mar;21(3):386-388. doi: 10.1002/ejhf.1419. Epub 2019 Feb 14. No abstract available.

PMID:
30767353
18.

Will the FAbry STabilization indEX make its way to everyday clinical practice?

Cairns T, Wanner C.

Clin Kidney J. 2019 Feb;12(1):61-64. doi: 10.1093/ckj/sfy126. Epub 2018 Dec 24.

19.

A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients.

Hammer F, Malzahn U, Donhauser J, Betz C, Schneider MP, Grupp C, Pollak N, Störk S, Wanner C, Krane V; MiREnDa Study Group.

Kidney Int. 2019 Apr;95(4):983-991. doi: 10.1016/j.kint.2018.11.025. Epub 2019 Jan 31.

PMID:
30712923
20.

Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial.

Inzucchi SE, Wanner C, Hehnke U, Zwiener I, Kaspers S, Clark D, George JT, Zinman B.

Diabetes Care. 2019 Apr;42(4):e53-e55. doi: 10.2337/dc18-1355. Epub 2019 Jan 31. No abstract available.

PMID:
30705060
21.

Differences in Dialysis Efficacy Have Limited Effects on Protein-Bound Uremic Toxins Plasma Levels over Time.

Krieter DH, Kerwagen S, Rüth M, Lemke HD, Wanner C.

Toxins (Basel). 2019 Jan 16;11(1). pii: E47. doi: 10.3390/toxins11010047.

22.

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.

McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, Toto RD, Zinman B, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, Marx N; CARMELINA Investigators.

Circulation. 2019 Jan 15;139(3):351-361. doi: 10.1161/CIRCULATIONAHA.118.038352.

PMID:
30586723
23.

Hot topics in Fabry disease.

Cairns T, Müntze J, Gernert J, Spingler L, Nordbeck P, Wanner C.

Postgrad Med J. 2018 Dec;94(1118):709-713. doi: 10.1136/postgradmedj-2018-136056. Epub 2018 Dec 17. Review.

PMID:
30559317
24.

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.

Herrington WG, Preiss D, Haynes R, von Eynatten M, Staplin N, Hauske SJ, George JT, Green JB, Landray MJ, Baigent C, Wanner C.

Clin Kidney J. 2018 Dec;11(6):749-761. doi: 10.1093/ckj/sfy090. Epub 2018 Oct 25. Review.

25.

Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year.

Müntze J, Gensler D, Maniuc O, Liu D, Cairns T, Oder D, Hu K, Lorenz K, Frantz S, Wanner C, Nordbeck P.

Clin Pharmacol Ther. 2019 May;105(5):1224-1233. doi: 10.1002/cpt.1321. Epub 2019 Jan 13.

PMID:
30506669
26.

Lancet Countdown paper: what does it mean for nephrology?

Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, Goumenos D, Massy Z, Rychlík I, Soler MJ, Spasovski G, Stevens K, Wanner C, Zoccali C.

Nephrol Dial Transplant. 2019 Jan 1;34(1):4-6. doi: 10.1093/ndt/gfy369. No abstract available.

PMID:
30496519
27.

Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor.

Dale DC, Bolyard AA, Marrero T, Kelley ML, Makaryan V, Tran E, Leung J, Boxer LA, Kishnani PS, Austin S, Wanner C, Ferrecchia IA, Khalaf D, Maze D, Kurtzberg J, Zeidler C, Welte K, Weinstein DA.

Curr Opin Hematol. 2019 Jan;26(1):16-21. doi: 10.1097/MOH.0000000000000474.

PMID:
30451720
28.

Variations in cardiovascular risk factors in people with and without migration background in Germany - Results from the STAAB cohort study.

Morbach C, Gelbrich G, Tiffe T, Eichner F, Wagner M, Heuschmann PU, Störk S; STAAB consortium, Frantz S, Maack C, Ertl G, Fassnacht M, Wanner C, Leyh R, Volkmann J, Deckert J, Faller H, Jahns R.

Int J Cardiol. 2019 Jul 1;286:186-189. doi: 10.1016/j.ijcard.2018.10.098. Epub 2018 Oct 30.

PMID:
30420145
29.

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK; CARMELINA Investigators.

JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269.

PMID:
30418475
30.

The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - A systematic literature review by a European panel of experts.

Germain DP, Arad M, Burlina A, Elliott PM, Falissard B, Feldt-Rasmussen U, Hilz MJ, Hughes DA, Ortiz A, Wanner C, Weidemann F, Spada M.

Mol Genet Metab. 2019 Mar;126(3):224-235. doi: 10.1016/j.ymgme.2018.09.007. Epub 2018 Sep 27. Review.

31.

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial.

Kadowaki T, Nangaku M, Hantel S, Okamura T, von Eynatten M, Wanner C, Koitka-Weber A.

J Diabetes Investig. 2019 May;10(3):760-770. doi: 10.1111/jdi.12971. Epub 2019 Jan 7.

32.

Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.

Lenders M, Neußer LP, Rudnicki M, Nordbeck P, Canaan-Kühl S, Nowak A, Cybulla M, Schmitz B, Lukas J, Wanner C, Brand SM, Brand E.

J Am Soc Nephrol. 2018 Dec;29(12):2879-2889. doi: 10.1681/ASN.2018070740. Epub 2018 Nov 1.

PMID:
30385651
33.

Cardiac Troponins for the Diagnosis of Acute Myocardial Infarction in Chronic Kidney Disease.

Kraus D, von Jeinsen B, Tzikas S, Palapies L, Zeller T, Bickel C, Fette G, Lackner KJ, Drechsler C, Neumann JT, Baldus S, Blankenberg S, Münzel T, Wanner C, Zeiher AM, Keller T.

J Am Heart Assoc. 2018 Oct 2;7(19):e008032. doi: 10.1161/JAHA.117.008032.

34.

Response by Wanner et al to Letters Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".

Wanner C, von Eynatten M, Zinman B.

Circulation. 2018 Aug 21;138(8):850-851. doi: 10.1161/CIRCULATIONAHA.118.035881. No abstract available.

PMID:
30359123
35.

Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease.

Scheppach JB, Raff U, Toncar S, Ritter C, Klink T, Störk S, Wanner C, Schlieper G, Saritas T, Reinartz SD, Floege J, Janka R, Uder M, Schmieder RE, Eckardt KU, Schneider MP.

Hypertension. 2018 Oct;72(4):929-936. doi: 10.1161/HYPERTENSIONAHA.118.11608.

PMID:
30354716
36.

Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.

Inzucchi SE, Kosiborod M, Fitchett D, Wanner C, Hehnke U, Kaspers S, George JT, Zinman B.

Circulation. 2018 Oct 23;138(17):1904-1907. doi: 10.1161/CIRCULATIONAHA.118.035759. No abstract available.

PMID:
30354665
38.

Farewell Editorial.

Burrowes JD, Wanner C.

J Ren Nutr. 2018 Nov;28(6):367-368. doi: 10.1053/j.jrn.2018.07.002. No abstract available.

PMID:
30348258
39.

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.

Wanner C, Heerspink HJL, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, Hantel S, Woerle HJ, Broedl UC, von Eynatten M, Groop PH; EMPA-REG OUTCOME Investigators.

J Am Soc Nephrol. 2018 Nov;29(11):2755-2769. doi: 10.1681/ASN.2018010103. Epub 2018 Oct 12.

PMID:
30314978
40.

Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology.

Maack C, Lehrke M, Backs J, Heinzel FR, Hulot JS, Marx N, Paulus WJ, Rossignol P, Taegtmeyer H, Bauersachs J, Bayes-Genis A, Brutsaert D, Bugger H, Clarke K, Cosentino F, De Keulenaer G, Dei Cas A, González A, Huelsmann M, Iaccarino G, Lunde IG, Lyon AR, Pollesello P, Rena G, Riksen NP, Rosano G, Staels B, van Laake LW, Wanner C, Farmakis D, Filippatos G, Ruschitzka F, Seferovic P, de Boer RA, Heymans S.

Eur Heart J. 2018 Dec 21;39(48):4243-4254. doi: 10.1093/eurheartj/ehy596. No abstract available.

41.

Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.

Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, Drechsler C, Wanner C, Mora S, Lesogor A, Tsimikas S.

Lancet. 2018 Oct 13;392(10155):1311-1320. doi: 10.1016/S0140-6736(18)31652-0. Epub 2018 Oct 4.

PMID:
30293769
42.

Correction: Blood pressure control in chronic kidney disease: A cross-sectional analysis from the German Chronic Kidney Disease (GCKD) study.

Schneider MP, Hilgers KF, Schmid M, Hübner S, Nadal J, Seitz D, Busch M, Haller H, Köttgen A, Kronenberg F, Baid-Agrawal S, Schlieper G, Schultheiss U, Sitter T, Sommerer C, Titze S, Meiselbach H, Wanner C, Eckardt KU; GCKD Study Investigators.

PLoS One. 2018 Sep 13;13(9):e0204340. doi: 10.1371/journal.pone.0204340. eCollection 2018.

43.

Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study.

Reinecke H, Jürgensmeyer S, Engelbertz C, Gerss J, Kirchhof P, Breithardt G, Bauersachs R, Wanner C.

BMJ Open. 2018 Sep 10;8(9):e022690. doi: 10.1136/bmjopen-2018-022690.

44.

Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes-A Proposed MARE Definition.

Prischl FC, Wanner C.

Kidney Int Rep. 2018 Apr 22;3(5):1030-1038. doi: 10.1016/j.ekir.2018.04.008. eCollection 2018 Sep. Review.

45.

SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases.

Wanner C, Marx N.

Diabetologia. 2018 Oct;61(10):2134-2139. doi: 10.1007/s00125-018-4678-z. Epub 2018 Aug 22. Review.

PMID:
30132035
46.

Blood pressure control in chronic kidney disease: A cross-sectional analysis from the German Chronic Kidney Disease (GCKD) study.

Schneider MP, Hilgers KF, Schmid M, Hübner S, Nadal J, Seitz D, Busch M, Haller H, Köttgen A, Kronenberg F, Baid-Agrawal S, Schlieper G, Schultheiss U, Sitter T, Sommerer C, Titze S, Meiselbach H, Wanner C, Eckardt KU; GCKD Study Investigators.

PLoS One. 2018 Aug 20;13(8):e0202604. doi: 10.1371/journal.pone.0202604. eCollection 2018. Erratum in: PLoS One. 2018 Sep 13;13(9):e0204340.

47.

The ABCs in the Mapping Progress in Reducing Cardiovascular Risk with Kidney Disease: An Introductory Remark on Expert Perspectives.

Wanner C.

Clin J Am Soc Nephrol. 2018 Sep 7;13(9):1421-1422. doi: 10.2215/CJN.09090718. Epub 2018 Aug 15. No abstract available.

PMID:
30111587
48.

Characterization of vertigo and hearing loss in patients with Fabry disease.

Köping M, Shehata-Dieler W, Schneider D, Cebulla M, Oder D, Müntze J, Nordbeck P, Wanner C, Hagen R, Schraven SP.

Orphanet J Rare Dis. 2018 Aug 15;13(1):137. doi: 10.1186/s13023-018-0882-7.

49.

Association and diagnostic utility of diastolic dysfunction and myocardial fibrosis in patients with Fabry disease.

Liu D, Oder D, Salinger T, Hu K, Müntze J, Weidemann F, Herrmann S, Ertl G, Wanner C, Frantz S, Störk S, Nordbeck P.

Open Heart. 2018 Jul 12;5(2):e000803. doi: 10.1136/openhrt-2018-000803. eCollection 2018.

50.

European expert consensus statement on therapeutic goals in Fabry disease.

Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, Fomin VV, Germain DP, Hughes DA, Jovanovic A, Kantola I, Linhart A, Mignani R, Monserrat L, Namdar M, Nowak A, Oliveira JP, Ortiz A, Pieroni M, Spada M, Tylki-Szymańska A, Tøndel C, Viana-Baptista M, Weidemann F, Hilz MJ.

Mol Genet Metab. 2018 Jul;124(3):189-203. doi: 10.1016/j.ymgme.2018.06.004. Epub 2018 Jun 12. Review.

PMID:
30017653

Supplemental Content

Loading ...
Support Center